首页 > 最新文献

Obstetrics and Gynecology Science最新文献

英文 中文
Clinical outcome after high dose rate intracavitary brachytherapy with traditional point 'A' dose prescription in locally advanced carcinoma of uterine cervix: dosimetric analysis from the perspective of computed tomography imaging-based 3-dimensional treatment planning. 传统A点剂量处方HDR腔内近距离治疗局部晚期宫颈癌的临床结果:基于CT成像的三维治疗计划的剂量分析。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-10-11 DOI: 10.5468/ogs.23048
Suman Dhabal, Abhishek Basu, Saikat Sau, Sourav Sau, Pradip Kumar Maiti, Abhay Chakravarty

Objective: To analyze tumour response and toxicity with respect to cumulative radiotherapy dose to target and organs at risk (OARs) with computed tomography (CT)-based image guided adaptive brachytherapy planning for locally advanced carcinoma cervix.

Methods: Patients were treated with two-dimensional concurrent chemoradiotherapy to whole pelvis followed by intracavitary brachytherapy (ICBT) with dose prescription to point 'A'. CT image-based delineation of high-risk clinical target volume (HR-CTV), urinary bladder, rectum and sigmoid colon was done with generation of dose-volume histogram (DVH) data and optimization of doses to target and OARs. Follow up assessments were done for response of disease and toxicity with generation of data for statistical analysis.

Results: One hundred thirty-six patients were enrolled in the study. Delineated volume of HR-CTV ranged from 20.9 to 37.1 mL, with median value of 30.2 mL. The equivalent dose in 2 Gy per fraction (EQD2) for point 'A' ranged from 71.31 to 79.75 Gy with median value of 75.1 Gy and EQD2 HR-CTV D90 ranged from 71.9 to 89.7 Gy with median value of 85.1 Gy. 69.2% of patients showed complete response and after median follow-up of 25 months, 50 patients remained disease free, of whom, 74.0% had received ≥85 Gy to HR-CTV D90 versus 26.0% receiving <85 Gy to HR-CTV D90.

Conclusion: s Amidst the unavailability of magnetic resonance imaging facilities in low middle income countries, incorporation of CT-image based treatment planning into routine practice for ICBT provides the scope to delineate volumes of target and OARs and to generate DVH data, which can prove to be a better surrogate for disease response and toxicity.

目的:应用基于计算机断层扫描(CT)的图像引导自适应近距离放射治疗计划,从靶点和危险器官的累积放射剂量角度分析局部晚期宫颈癌患者的肿瘤反应和毒性。方法:对患者进行全骨盆二维同步放化疗,然后进行剂量处方为“A”点的腔内近距离放射治疗(ICBT)。通过生成剂量-体积直方图(DVH)数据并优化目标和OAR的剂量,进行基于CT图像的规划,描绘高危临床目标体积(HR-CTV)、膀胱、直肠和乙状结肠。对疾病反应和晚期毒性进行了随访评估,并生成了用于统计分析的数据。结果:本研究纳入136名患者。划定的HR-CTV范围为20.9立方厘米至37.1立方厘米,中位数为30.2立方厘米。点“a”的等效剂量(2 Gy/次)范围为71.31 Gy至79.75 Gy,中位数为75.1 Gy,EQD2 HR-CTV D90范围为71.9 Gy至89.7 Gy,中值为85.1 Gy。在患者中,69.2%显示完全缓解。经过25个月的中位随访,50名患者保持无病状态,其中74.0%接受≥85 Gy HR-CTV D90治疗,26.0%接受90治疗。结论:在中低收入国家缺乏磁共振设备的情况下,将基于CT图像的治疗计划纳入ICBT的常规实践提供了描绘靶点和OAR体积以及生成DVH数据的范围,DVH数据可以被证明是疾病反应和毒性的更好替代品。
{"title":"Clinical outcome after high dose rate intracavitary brachytherapy with traditional point 'A' dose prescription in locally advanced carcinoma of uterine cervix: dosimetric analysis from the perspective of computed tomography imaging-based 3-dimensional treatment planning.","authors":"Suman Dhabal, Abhishek Basu, Saikat Sau, Sourav Sau, Pradip Kumar Maiti, Abhay Chakravarty","doi":"10.5468/ogs.23048","DOIUrl":"10.5468/ogs.23048","url":null,"abstract":"<p><strong>Objective: </strong>To analyze tumour response and toxicity with respect to cumulative radiotherapy dose to target and organs at risk (OARs) with computed tomography (CT)-based image guided adaptive brachytherapy planning for locally advanced carcinoma cervix.</p><p><strong>Methods: </strong>Patients were treated with two-dimensional concurrent chemoradiotherapy to whole pelvis followed by intracavitary brachytherapy (ICBT) with dose prescription to point 'A'. CT image-based delineation of high-risk clinical target volume (HR-CTV), urinary bladder, rectum and sigmoid colon was done with generation of dose-volume histogram (DVH) data and optimization of doses to target and OARs. Follow up assessments were done for response of disease and toxicity with generation of data for statistical analysis.</p><p><strong>Results: </strong>One hundred thirty-six patients were enrolled in the study. Delineated volume of HR-CTV ranged from 20.9 to 37.1 mL, with median value of 30.2 mL. The equivalent dose in 2 Gy per fraction (EQD2) for point 'A' ranged from 71.31 to 79.75 Gy with median value of 75.1 Gy and EQD2 HR-CTV D90 ranged from 71.9 to 89.7 Gy with median value of 85.1 Gy. 69.2% of patients showed complete response and after median follow-up of 25 months, 50 patients remained disease free, of whom, 74.0% had received ≥85 Gy to HR-CTV D90 versus 26.0% receiving <85 Gy to HR-CTV D90.</p><p><strong>Conclusion: </strong>s Amidst the unavailability of magnetic resonance imaging facilities in low middle income countries, incorporation of CT-image based treatment planning into routine practice for ICBT provides the scope to delineate volumes of target and OARs and to generate DVH data, which can prove to be a better surrogate for disease response and toxicity.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"67-75"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A glance into the roles of microRNAs (exosomal and non-exosomal) in polycystic ovary syndrome. 微rna(外泌体和非外泌体)在多囊卵巢综合征中的作用
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-05 DOI: 10.5468/ogs.23193
Afsane Masoudi Chelegahi, Seyed Omar Ebrahimi, Somayeh Reiisi, Maria Nezamnia

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women of reproductive age. The clinical symptoms include hyperandrogenism, chronic anovulation, and multiple ovarian cysts. PCOS is strongly associated with obesity and insulin resistance. MicroRNAs (miRNAs) are a group of short non-coding RNAs that play a role in the post-transcriptional regulation of gene expression and translational inhibition. They play a vital role in the regulation of multiple metabolic and hormonal processes as well as in oocyte maturation and folliculogenesis in the female reproductive system. miRNAs can be used as diagnostic biomarkers or therapeutic targets because of their stability. The encapsulation of miRNAs in extracellular vesicles or exosomes contributes to their stability. Exosomes are constantly secreted by many cells and size of about 30 to 150 nm. Enveloping miRNAs exosomes can release them for cellular communication. The induced transfer of miRNAs by exosomes is a novel process of genetic exchange between cells. Many studies have shown that along with non-exosomal miRNAs, different types of exosomal miRNAs derived from the serum and follicular fluid can play an essential role in PCOS pathogenesis. These miRNAs are involved in follicular development and various functions in granulosa cells, apoptosis, cell proliferation, and follicular atresia. The present study aimed to comprehensively review the evidence on miRNAs and their affected pathways under both non-exosomal and exosomal circumstances, primarily focusing on the pathogenesis of PCOS.

多囊卵巢综合征(PCOS)是育龄妇女常见的内分泌疾病。临床表现为雄激素分泌亢进、慢性无排卵、多发卵巢囊肿。多囊卵巢综合征与肥胖和胰岛素抵抗密切相关。MicroRNAs是一组短的非编码rna,在基因表达的转录后调控和翻译抑制中发挥作用。它们在调节女性生殖系统的多种代谢和激素过程以及卵母细胞成熟和卵泡发生中发挥重要作用。由于其稳定性,mirna可作为诊断性生物标志物或治疗靶点。mirna在细胞外囊泡或外泌体中的包封有助于其稳定性。外泌体由许多细胞不断分泌,大小约为30至150纳米。包裹mirna的外泌体可以释放它们用于细胞通讯。外泌体诱导的mirna转移是细胞间遗传交换的新过程。许多研究表明,与非外泌体mirna一起,来自血清和卵泡液的不同类型的外泌体mirna在PCOS发病过程中发挥重要作用。这些mirna参与滤泡发育和颗粒细胞、细胞凋亡、细胞增殖和滤泡闭锁的各种功能。本研究旨在全面回顾非外泌体和外泌体情况下mirna及其影响途径的证据,主要关注PCOS的发病机制。
{"title":"A glance into the roles of microRNAs (exosomal and non-exosomal) in polycystic ovary syndrome.","authors":"Afsane Masoudi Chelegahi, Seyed Omar Ebrahimi, Somayeh Reiisi, Maria Nezamnia","doi":"10.5468/ogs.23193","DOIUrl":"10.5468/ogs.23193","url":null,"abstract":"<p><p>Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women of reproductive age. The clinical symptoms include hyperandrogenism, chronic anovulation, and multiple ovarian cysts. PCOS is strongly associated with obesity and insulin resistance. MicroRNAs (miRNAs) are a group of short non-coding RNAs that play a role in the post-transcriptional regulation of gene expression and translational inhibition. They play a vital role in the regulation of multiple metabolic and hormonal processes as well as in oocyte maturation and folliculogenesis in the female reproductive system. miRNAs can be used as diagnostic biomarkers or therapeutic targets because of their stability. The encapsulation of miRNAs in extracellular vesicles or exosomes contributes to their stability. Exosomes are constantly secreted by many cells and size of about 30 to 150 nm. Enveloping miRNAs exosomes can release them for cellular communication. The induced transfer of miRNAs by exosomes is a novel process of genetic exchange between cells. Many studies have shown that along with non-exosomal miRNAs, different types of exosomal miRNAs derived from the serum and follicular fluid can play an essential role in PCOS pathogenesis. These miRNAs are involved in follicular development and various functions in granulosa cells, apoptosis, cell proliferation, and follicular atresia. The present study aimed to comprehensively review the evidence on miRNAs and their affected pathways under both non-exosomal and exosomal circumstances, primarily focusing on the pathogenesis of PCOS.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"30-48"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival probabilities and prognostic factors of pregnancy-associated breast cancer in Malaysian women. 马来西亚妇女妊娠相关乳腺癌的生存概率和预后因素。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-21 DOI: 10.5468/ogs.23151
S S Abrar, Bachok Norsa'adah, Maya Mazuwin Yahya, Junaidi A Isa, Erinna M Zon

Objective: Pregnancy-associated breast cancer (PABC) is a rare cancer. This study aimed to determine the survival probabilities and prognostic factors in patients with PABC.

Methods: A retrospective cohort study was conducted in two tertiary care hospitals in Kota Bharu. We included all patients with breast cancer who were diagnosed by histopathology while pregnant or within 2 years post-partum from 2001 through 2020. We matched patients with PABC to non-pregnant patients with breast cancer by age and year of diagnosis. The data were analyzed using Cox proportional hazard regression.

Results: A total of 35 cases of PABC and 70 non-PABC controls were recruited. The 3-year, 5-year, and 10-year survival probabilities for patients with PABC were 58.6%, 47.54%, and 38.03%, respectively. The patients with PABC had a non-significant difference in survival probabilities compared with non-PABC patients. The significant prognostic factors of PABC were age (adjusted hazard ratio [aHR], 0.91; 95% confidence interval [CI], 0.86-0.96; P=0.001), advanced stage of cancer (aHR, 9.97; 95% CI, 3.96-25.2; P<0.001), and no surgery (aHR, 3.16; 95% CI, 1.01-9.85; P=0.047). Pregnancy was not found to be an independent factor in the prognosis of PABC (aHR, 0.72; 95% CI, 0.39-1.28; P=0.266).

Conclusion: Women diagnosed with PABC had similar survival probabilities compared with non-PABC patients. Pregnancy was not an independent prognostic factor for breast cancer. This information can be useful when women with breast cancer are counseled and supported with the option of beginning treatment with pregnancy continuation.

目的:妊娠相关乳腺癌(PABC)是一种罕见的癌症。本研究旨在确定PABC患者的生存概率和预后因素。方法:在哥打巴鲁的两家三级医院进行回顾性队列研究。我们纳入了2001年至2020年期间通过组织病理学诊断为怀孕期间或产后2年内的所有乳腺癌患者。我们将PABC患者与未怀孕的乳腺癌患者按年龄和诊断年份进行匹配。采用Cox比例风险回归分析数据。结果:共纳入35例PABC患者和70例非PABC对照组。PABC患者的3年、5年和10年生存率分别为58.6%、47.54%和38.03%。与非PABC患者相比,PABC患者的生存概率无显著差异。PABC的显著预后因素为年龄(校正风险比[aHR] 0.91, 95%可信区间[CI], 0.86-0.96;P=0.001),晚期癌症(aHR, 9.97, 95% CI, 3.96-25.2;结论:诊断为PABC的女性与非PABC患者的生存率相似。妊娠并不是乳腺癌的独立预后因素。当患有乳腺癌的妇女得到咨询和支持,选择开始治疗并继续妊娠时,这些信息是有用的。
{"title":"Survival probabilities and prognostic factors of pregnancy-associated breast cancer in Malaysian women.","authors":"S S Abrar, Bachok Norsa'adah, Maya Mazuwin Yahya, Junaidi A Isa, Erinna M Zon","doi":"10.5468/ogs.23151","DOIUrl":"10.5468/ogs.23151","url":null,"abstract":"<p><strong>Objective: </strong>Pregnancy-associated breast cancer (PABC) is a rare cancer. This study aimed to determine the survival probabilities and prognostic factors in patients with PABC.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted in two tertiary care hospitals in Kota Bharu. We included all patients with breast cancer who were diagnosed by histopathology while pregnant or within 2 years post-partum from 2001 through 2020. We matched patients with PABC to non-pregnant patients with breast cancer by age and year of diagnosis. The data were analyzed using Cox proportional hazard regression.</p><p><strong>Results: </strong>A total of 35 cases of PABC and 70 non-PABC controls were recruited. The 3-year, 5-year, and 10-year survival probabilities for patients with PABC were 58.6%, 47.54%, and 38.03%, respectively. The patients with PABC had a non-significant difference in survival probabilities compared with non-PABC patients. The significant prognostic factors of PABC were age (adjusted hazard ratio [aHR], 0.91; 95% confidence interval [CI], 0.86-0.96; P=0.001), advanced stage of cancer (aHR, 9.97; 95% CI, 3.96-25.2; P<0.001), and no surgery (aHR, 3.16; 95% CI, 1.01-9.85; P=0.047). Pregnancy was not found to be an independent factor in the prognosis of PABC (aHR, 0.72; 95% CI, 0.39-1.28; P=0.266).</p><p><strong>Conclusion: </strong>Women diagnosed with PABC had similar survival probabilities compared with non-PABC patients. Pregnancy was not an independent prognostic factor for breast cancer. This information can be useful when women with breast cancer are counseled and supported with the option of beginning treatment with pregnancy continuation.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"76-85"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138177497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age of first experience of gender incongruence among transgender and non-binary individuals. 跨性别者与非二元性别者首次经历性别不一致的年龄。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-04 DOI: 10.5468/ogs.23229
Jeong-Won Oh, Sohee Park, Seongyun Lim, Eun Sil Lee

Objective: Gender incongruence (GI) is a condition in which an individual's gender identity, role, and expression differ from their assigned sex. This study aimed to evaluate when GI first arises in transgender and non-binary individuals seeking hormone therapy and their years living untreated in South Korea.

Methods: This retrospective study analyzed GI patients seeking gender-affirming hormone therapy (GAHT) or surgery between 2015 and 2021. The recorded data included gender identity, legal transition status, age of onset of GI, age at the initiation of therapy, and total therapy duration.

Results: In total, 337 patients were enrolled, including 149 (44.2%) transgender men, 153 (45.4%) transgender women, and 35 (10.4%) non-binary individuals. The mean age of onset of GI was 10.6 years (standard deviation, 5.1). Of the total patients, 29% had an onset of GI before age 6 years (preschool), 61% before age 12 (elementary-school), and 87% before age 15 (middle-school). Patients lived with GI for almost 14 years before GAHT initiation at a median age of 23.0 years. 90% of transgender men, 82.3% of transgender women, and 85% of non-binary patients disclosed their gender identities to their families. Regarding social transition, 31.5% of transgender men, 16.3% of transgender women, and none of the non-binary patients (P<0.005) changed their legal gender markers.

Conclusion: Many transgender and non-binary individuals experience GI early in life. These findings emphasized the need for early evaluation, timely gender-affirming care, and more accessible legal processes for gender marker changes in South Korea, aiming to enhance the safety and well-being of these individuals.

目的:性别不一致(GI)是指个体的性别认同、角色和表达与其生理性别不同的一种状况。本研究旨在评估在韩国寻求激素治疗的跨性别和非二元性个体何时首次出现GI,以及他们未经治疗的生活年限。方法:本回顾性研究分析了2015年至2021年间寻求性别确认激素治疗(GAHT)或手术的胃肠道患者。记录的数据包括性别认同、合法过渡状态、GI发病年龄、开始治疗年龄和总治疗时间。结果:共纳入337例患者,其中变性男性149例(44.2%),变性女性153例(45.4%),非二元性个体35例(10.4%)。GI的平均发病年龄为10.6岁(标准差为5.1)。在所有患者中,29%在6岁前(学龄前)发病,61%在12岁前(小学)发病,87%在15岁前(中学)发病。在GAHT开始治疗前,患者与胃肠道共存了近14年,中位年龄为23.0岁。90%的跨性别男性、82.3%的跨性别女性和85%的非二元性别患者向家人公开了自己的性别认同。在社会转变方面,31.5%的跨性别男性,16.3%的跨性别女性,没有非二元性别患者(结论:许多跨性别和非二元性别患者在生命早期经历过GI。这些发现强调了韩国需要对性别标志变化进行早期评估、及时的性别确认护理和更容易获得的法律程序,以提高这些人的安全和福祉。
{"title":"Age of first experience of gender incongruence among transgender and non-binary individuals.","authors":"Jeong-Won Oh, Sohee Park, Seongyun Lim, Eun Sil Lee","doi":"10.5468/ogs.23229","DOIUrl":"10.5468/ogs.23229","url":null,"abstract":"<p><strong>Objective: </strong>Gender incongruence (GI) is a condition in which an individual's gender identity, role, and expression differ from their assigned sex. This study aimed to evaluate when GI first arises in transgender and non-binary individuals seeking hormone therapy and their years living untreated in South Korea.</p><p><strong>Methods: </strong>This retrospective study analyzed GI patients seeking gender-affirming hormone therapy (GAHT) or surgery between 2015 and 2021. The recorded data included gender identity, legal transition status, age of onset of GI, age at the initiation of therapy, and total therapy duration.</p><p><strong>Results: </strong>In total, 337 patients were enrolled, including 149 (44.2%) transgender men, 153 (45.4%) transgender women, and 35 (10.4%) non-binary individuals. The mean age of onset of GI was 10.6 years (standard deviation, 5.1). Of the total patients, 29% had an onset of GI before age 6 years (preschool), 61% before age 12 (elementary-school), and 87% before age 15 (middle-school). Patients lived with GI for almost 14 years before GAHT initiation at a median age of 23.0 years. 90% of transgender men, 82.3% of transgender women, and 85% of non-binary patients disclosed their gender identities to their families. Regarding social transition, 31.5% of transgender men, 16.3% of transgender women, and none of the non-binary patients (P<0.005) changed their legal gender markers.</p><p><strong>Conclusion: </strong>Many transgender and non-binary individuals experience GI early in life. These findings emphasized the need for early evaluation, timely gender-affirming care, and more accessible legal processes for gender marker changes in South Korea, aiming to enhance the safety and well-being of these individuals.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"132-141"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. 补充α -硫辛酸对多囊卵巢综合征患者的人体测量、血糖、血脂、氧化应激和激素参数的影响:随机临床试验的系统回顾和荟萃分析。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-04 DOI: 10.5468/ogs.23206
Ahmed Abu-Zaid, Saeed Baradwan, Ibtihal Abdulaziz Bukhari, Abdullah Alyousef, Mohammed Abuzaid, Saleh A K Saleh, Heba M Adly, Osama Alomar, Ismail Abdulrahman Al-Badawi

This systematic review and meta-analysis aimed to examine the effect of the antioxidant alpha-lipoic acid (ALA) on various cardiometabolic risk factors and hormonal parameters in patients with polycystic ovary syndrome (PCOS). We searched PubMed, EMBASE, SCOPUS, Cochrane Library, and Web of Science databases without language restrictions until May 2023 to find randomized controlled trials (RCTs) that assessed the impact of ALA supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in women with PCOS. Outcomes were summarized using the standardized mean difference (SMD) and 95% confidence interval (CI) in a random-effects model. An I2 statistic of >60% established significant between-study heterogeneity. The overall certainty of the evidence for each outcome was determined using the grading of recommendations, assessment, development, and evaluations system. Seven RCTs met the inclusion criteria. The ALA group had significant reductions in fasting blood sugar (fasting blood sugar (FBS), n=7 RCTs, SMD, -0.60; 95% CI, -1.10 to -0.10; I2=63.54%, moderate certainty of evidence) and homeostatic model assessment for insulin resistance (homeostatic model assessment of insulin resistance (HOMA-IR), n=4 RCTs, SMD, -2.03; 95% CI, -3.85 to -0.20; I2=96.32%, low certainty of evidence) compared with the control group. However, significant differences were observed between the groups in body mass index, insulin, estrogen, follicle-stimulating hormone, luteinizing hormone, testosterone, low-density lipoprotein, highdensity lipoprotein, triglyceride, total cholesterol, malondialdehyde, or total antioxidant capacity profiles. ALA supplementation improves FBS and HOMA-IR levels in women with PCOS. ALA consumption is an effective complementary therapy for the management of women with PCOS.

本系统综述和荟萃分析旨在探讨抗氧化剂α -硫辛酸(ALA)对多囊卵巢综合征(PCOS)患者各种心脏代谢危险因素和激素参数的影响。我们检索了PubMed、EMBASE、SCOPUS、Cochrane Library和Web of Science数据库,没有语言限制,直到2023年5月,找到评估ALA补充对PCOS女性人体测量、血糖、脂质、氧化应激和激素参数影响的随机对照试验(RCTs)。采用随机效应模型中的标准化平均差(SMD)和95%置信区间(CI)对结果进行总结。I2统计值>60%表明研究间存在显著异质性。采用推荐、评估、发展和评价分级(GRADE)系统确定每个结果证据的总体确定性。7项rct符合纳入标准。ALA组空腹血糖(FBS)显著降低;n = 7相关;SMD, -0.60;95% CI, -1.10 ~ -0.10;I2=63.54%,证据确定性中等)和胰岛素抵抗的稳态模型评估(HOMA-IR;n = 4相关的;SMD, -2.03;95% CI, -3.85 ~ -0.20;I2=96.32%,证据确定性低)与对照组比较。然而,在体重指数、胰岛素、雌激素、促卵泡激素、黄体生成素、睾酮、低密度脂蛋白、高密度脂蛋白、甘油三酯、总胆固醇、丙二醛或总抗氧化能力方面,组间存在显著差异。补充ALA可改善PCOS女性的FBS和HOMA-IR水平。ALA消费是一种有效的补充治疗的妇女与多囊卵巢综合征的管理。
{"title":"The effect of alpha-lipoic acid supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in individuals with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.","authors":"Ahmed Abu-Zaid, Saeed Baradwan, Ibtihal Abdulaziz Bukhari, Abdullah Alyousef, Mohammed Abuzaid, Saleh A K Saleh, Heba M Adly, Osama Alomar, Ismail Abdulrahman Al-Badawi","doi":"10.5468/ogs.23206","DOIUrl":"10.5468/ogs.23206","url":null,"abstract":"<p><p>This systematic review and meta-analysis aimed to examine the effect of the antioxidant alpha-lipoic acid (ALA) on various cardiometabolic risk factors and hormonal parameters in patients with polycystic ovary syndrome (PCOS). We searched PubMed, EMBASE, SCOPUS, Cochrane Library, and Web of Science databases without language restrictions until May 2023 to find randomized controlled trials (RCTs) that assessed the impact of ALA supplementation on anthropometric, glycemic, lipid, oxidative stress, and hormonal parameters in women with PCOS. Outcomes were summarized using the standardized mean difference (SMD) and 95% confidence interval (CI) in a random-effects model. An I2 statistic of >60% established significant between-study heterogeneity. The overall certainty of the evidence for each outcome was determined using the grading of recommendations, assessment, development, and evaluations system. Seven RCTs met the inclusion criteria. The ALA group had significant reductions in fasting blood sugar (fasting blood sugar (FBS), n=7 RCTs, SMD, -0.60; 95% CI, -1.10 to -0.10; I2=63.54%, moderate certainty of evidence) and homeostatic model assessment for insulin resistance (homeostatic model assessment of insulin resistance (HOMA-IR), n=4 RCTs, SMD, -2.03; 95% CI, -3.85 to -0.20; I2=96.32%, low certainty of evidence) compared with the control group. However, significant differences were observed between the groups in body mass index, insulin, estrogen, follicle-stimulating hormone, luteinizing hormone, testosterone, low-density lipoprotein, highdensity lipoprotein, triglyceride, total cholesterol, malondialdehyde, or total antioxidant capacity profiles. ALA supplementation improves FBS and HOMA-IR levels in women with PCOS. ALA consumption is an effective complementary therapy for the management of women with PCOS.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"17-29"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fetal and maternal outcomes of segmental uterine resection in emergency and planned placenta percreta deliveries. 剖宫产切除术在紧急分娩和有计划的胎盘分娩中的胎儿和母体结局。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-04 DOI: 10.5468/ogs.23154
Şükran Doğru, Fatih Akkuş, Aslı Altinordu Atci, Ülfet Sena Metin, Mehmet Uyar, Ali Acar

Objective: This study evaluated maternal and fetal outcomes of emergency uterine resection versus planned segmental uterine resection in patients with placenta percreta (PPC) and placenta previa (PP).

Methods: Patients with PP and PPC who underwent planned or emergency segmental uterine resection were included in this study. Demographic data, hemorrhagic morbidities, intra- and postoperative complications, length of hospital stay, surgical duration, and peri- and neonatal morbidities were compared.

Results: A total of 141 PPC and PP cases were included in this study. Twenty-five patients (17.73%) underwent emergency uterine resection, while 116 (82.27%) underwent planned segmental uterine resections. The postoperative hemoglobin changes, operation times, total blood transfusion, bladder injury, and length of hospital stay did not differ significantly between groups (P=0.7, P=0.6, P=0.9, P=0.9, and P=0.2, respectively). Fetal weights, 5-minute Apgar scores, and neonatal intensive care unit admission rates did not differ significantly between groups. The gestational age at delivery of patients presenting with bleeding was lower than that of patients who were admitted in active labor and underwent elective surgery (32 weeks [95% confidence interval [CI], 26-37] vs. 35 weeks [95% CI, 34-35]; P=0.037).

Conclusion: Using a multidisciplinary approach, this study performed at a tertiary center showed that maternal and fetal morbidity and mortality did not differ significantly between emergency versus planned segmental uterine resection.

目的:本研究评价急诊子宫切除术与计划节段性子宫切除术对先天性胎盘(PPC)和前置胎盘(PP)患者的母婴预后。方法:本研究纳入了计划或紧急子宫节段切除术的PP和PPC患者。比较了人口统计学数据、出血性发病率、手术内和术后并发症、住院时间、手术时间、围产儿和新生儿发病率。结果:本研究共纳入141例PPC和PP病例。急诊子宫切除术25例(17.73%),计划节段性子宫切除术116例(82.27%)。两组患者术后血红蛋白变化、手术次数、总输血量、膀胱损伤、住院时间差异无统计学意义(P=0.7、P=0.6、P=0.9、P=0.9、P=0.2)。胎儿体重、5分钟Apgar评分和新生儿重症监护病房入院率在组间无显著差异。出血患者分娩时的胎龄低于主动分娩并接受择期手术的患者(32周[95%可信区间[CI], 26-37周]vs. 35周[95% CI, 34-35周],P=0.037)。结论:采用多学科方法,本研究在三级中心进行,显示产妇和胎儿的发病率和死亡率在急诊和计划的节段性子宫切除术之间没有显著差异。
{"title":"Fetal and maternal outcomes of segmental uterine resection in emergency and planned placenta percreta deliveries.","authors":"Şükran Doğru, Fatih Akkuş, Aslı Altinordu Atci, Ülfet Sena Metin, Mehmet Uyar, Ali Acar","doi":"10.5468/ogs.23154","DOIUrl":"10.5468/ogs.23154","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated maternal and fetal outcomes of emergency uterine resection versus planned segmental uterine resection in patients with placenta percreta (PPC) and placenta previa (PP).</p><p><strong>Methods: </strong>Patients with PP and PPC who underwent planned or emergency segmental uterine resection were included in this study. Demographic data, hemorrhagic morbidities, intra- and postoperative complications, length of hospital stay, surgical duration, and peri- and neonatal morbidities were compared.</p><p><strong>Results: </strong>A total of 141 PPC and PP cases were included in this study. Twenty-five patients (17.73%) underwent emergency uterine resection, while 116 (82.27%) underwent planned segmental uterine resections. The postoperative hemoglobin changes, operation times, total blood transfusion, bladder injury, and length of hospital stay did not differ significantly between groups (P=0.7, P=0.6, P=0.9, P=0.9, and P=0.2, respectively). Fetal weights, 5-minute Apgar scores, and neonatal intensive care unit admission rates did not differ significantly between groups. The gestational age at delivery of patients presenting with bleeding was lower than that of patients who were admitted in active labor and underwent elective surgery (32 weeks [95% confidence interval [CI], 26-37] vs. 35 weeks [95% CI, 34-35]; P=0.037).</p><p><strong>Conclusion: </strong>Using a multidisciplinary approach, this study performed at a tertiary center showed that maternal and fetal morbidity and mortality did not differ significantly between emergency versus planned segmental uterine resection.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"58-66"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytomegalovirus infection during pregnancy. 妊娠期巨细胞病毒感染。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2023-11-01 Epub Date: 2023-08-04 DOI: 10.5468/ogs.23117
Harshitha Kallubhavi Choodinatha, Min Ryeong Jeon, Bo Young Choi, Kyong-No Lee, Hyeon Ji Kim, Jee Yoon Park

Cytomegalovirus (CMV) infection during pregnancy is a global silent problem. Additionally, it is the leading cause of congenital infections, non-genetic sensorineural hearing loss, and neurodevelopmental delays in infants. However, this has barely been recognized globally. This condition lacks adequate attention, which is further emphasized by the lack of awareness among healthcare workers and the general population. The impact of CMV infection is often overlooked because of the asymptomatic nature of its presentation in infected pregnant women and newborns, difficulty in diagnosis, and the perception that infants born to women with pre-existing antibodies against CMV have normal neonatal outcomes. This article highlights the latest information on the epidemiology, transmission, clinical manifestations, and development of CMV infection and its management. We reviewed the pathophysiology and clinical manifestations of CMV infection in pregnant women, diagnostic methods, including screening and prognostic markers, and updates in treatment modalities. Current advancements in research on vaccination and hyperimmunoglobulins with worldwide treatment protocols are highlighted.

巨细胞病毒(CMV)感染是一个全球性的沉默问题。此外,它是先天性感染、非遗传性感音神经性听力损失和婴儿神经发育迟缓的主要原因。然而,这一点几乎没有得到全球的认可。这种情况缺乏足够的重视,卫生保健工作者和一般人群缺乏认识进一步强调了这一点。巨细胞病毒感染的影响常常被忽视,因为它在感染的孕妇和新生儿中表现为无症状,诊断困难,并且认为预先存在巨细胞病毒抗体的妇女所生的婴儿具有正常的新生儿结局。本文重点介绍巨细胞病毒感染的流行病学、传播、临床表现和发展及其管理方面的最新信息。我们回顾了孕妇巨细胞病毒感染的病理生理和临床表现,诊断方法,包括筛查和预后指标,以及治疗方式的最新进展。强调了目前在疫苗接种和超免疫球蛋白的研究进展以及全球治疗方案。
{"title":"Cytomegalovirus infection during pregnancy.","authors":"Harshitha Kallubhavi Choodinatha, Min Ryeong Jeon, Bo Young Choi, Kyong-No Lee, Hyeon Ji Kim, Jee Yoon Park","doi":"10.5468/ogs.23117","DOIUrl":"10.5468/ogs.23117","url":null,"abstract":"<p><p>Cytomegalovirus (CMV) infection during pregnancy is a global silent problem. Additionally, it is the leading cause of congenital infections, non-genetic sensorineural hearing loss, and neurodevelopmental delays in infants. However, this has barely been recognized globally. This condition lacks adequate attention, which is further emphasized by the lack of awareness among healthcare workers and the general population. The impact of CMV infection is often overlooked because of the asymptomatic nature of its presentation in infected pregnant women and newborns, difficulty in diagnosis, and the perception that infants born to women with pre-existing antibodies against CMV have normal neonatal outcomes. This article highlights the latest information on the epidemiology, transmission, clinical manifestations, and development of CMV infection and its management. We reviewed the pathophysiology and clinical manifestations of CMV infection in pregnant women, diagnostic methods, including screening and prognostic markers, and updates in treatment modalities. Current advancements in research on vaccination and hyperimmunoglobulins with worldwide treatment protocols are highlighted.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"463-476"},"PeriodicalIF":1.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9931450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical relevance of sentinel lymph node biopsy in early ovarian cancer. 早期卵巢癌症前哨淋巴结活检的临床意义。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2023-11-01 Epub Date: 2023-10-11 DOI: 10.5468/ogs.23114
Ki Eun Seon, Sang Wun Kim, Young Tae Kim

The first-line treatment for early ovarian cancer typically involves primary debulking surgery aimed at maximal cytoreduction, alongside adjuvant chemotherapy if clinically indicated. Nodal assessment involving pelvic and para-aortic lymph node dissection is typically performed during the primary debulking surgery. However, the survival benefit of lymphadenectomy in patients with early ovarian cancer has not been well established, and the procedure is associated with longer operation time and higher perioperative complications. With the emergence of minimally invasive surgery as a potential alternative to laparotomy for early ovarian cancer, sentinel lymph node biopsy has been evaluated in this setting. In this review, we summarized the current literature regarding sentinel lymph node biopsy in patients with early ovarian cancer, focusing on the clinical relevance of this method, including its detection rate and diagnostic accuracy. Additionally, we discuss the current status of clinical trials investigating sentinel lymph node biopsy in early ovarian cancer cases.

早期癌症的一线治疗通常包括旨在最大限度减少细胞的初级减瘤手术,以及临床指示的辅助化疗。涉及盆腔和主动脉旁淋巴结清扫的淋巴结评估通常在初次拆散手术期间进行。然而,淋巴结切除术对早期卵巢癌症患者的生存益处尚未得到很好的确定,而且该手术与较长的手术时间和较高的围手术期并发症有关。随着微创手术作为早期卵巢癌症剖腹手术的潜在替代方案的出现,前哨淋巴结活检已经在这种情况下进行了评估。在这篇综述中,我们总结了关于早期卵巢癌症患者前哨淋巴结活检的现有文献,重点介绍了这种方法的临床相关性,包括其检测率和诊断准确性。此外,我们还讨论了研究癌症早期前哨淋巴结活检的临床试验现状。
{"title":"Clinical relevance of sentinel lymph node biopsy in early ovarian cancer.","authors":"Ki Eun Seon, Sang Wun Kim, Young Tae Kim","doi":"10.5468/ogs.23114","DOIUrl":"10.5468/ogs.23114","url":null,"abstract":"<p><p>The first-line treatment for early ovarian cancer typically involves primary debulking surgery aimed at maximal cytoreduction, alongside adjuvant chemotherapy if clinically indicated. Nodal assessment involving pelvic and para-aortic lymph node dissection is typically performed during the primary debulking surgery. However, the survival benefit of lymphadenectomy in patients with early ovarian cancer has not been well established, and the procedure is associated with longer operation time and higher perioperative complications. With the emergence of minimally invasive surgery as a potential alternative to laparotomy for early ovarian cancer, sentinel lymph node biopsy has been evaluated in this setting. In this review, we summarized the current literature regarding sentinel lymph node biopsy in patients with early ovarian cancer, focusing on the clinical relevance of this method, including its detection rate and diagnostic accuracy. Additionally, we discuss the current status of clinical trials investigating sentinel lymph node biopsy in early ovarian cancer cases.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"498-508"},"PeriodicalIF":1.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative outcomes of ovarian preserving surgery in premenopausal women with adnexal torsion. 绝经前妇女附件扭转保留卵巢手术的术后结果。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2023-11-01 Epub Date: 2023-10-16 DOI: 10.5468/ogs.23071
Euna Choi, Hye In Kim, Seok Kyo Seo, Si Hyun Cho, Young Sik Choi, Byung Seok Lee, Bo Hyon Yun

Objective: We aimed to determine whether ovarian-preserving surgery for adnexal torsion helps preserve ovarian function without increasing the risk of postoperative complications.

Methods: We retrospectively evaluated 71 women who were surgically diagnosed with adnexal torsion between January 2015 and December 2019 at Severance Hospital, Yonsei University College of Medicine (ovarian preservation group, 56; oophorectomy, 15). Serum anti-Müllerian hormone (AMH) levels measured within 6 months before surgery were compared to levels measured 6-24 months after surgery. Surgical findings and postoperative complications were compared between the groups.

Results: There was a borderline significant difference in the decrease in serum AMH levels between the oophorectomy group and ovarian preservation group before and after surgery. There were no significant differences between the groups in terms of fever, infection, or duration of admission. Discoloration of the twisted ovary was found in 27.3% and 33.3% of the patients in the ovarian preservation and oophorectomy groups, respectively. There was no difference in the decrease in serum AMH levels between patients with and those without discoloration.

Conclusion: Ovarian-preserving surgery may not increase postoperative complications in patients with adnexal torsion, even if a twisted mass is suspected to be necrotic. Moreover, the ovarian reserve may not be affected by torsion if the ovary is preserved. Conservative ovarian surgery can be safely performed to preserve the reproductive potential of women with adnexal torsion and cystic masses.

目的:我们旨在确定附件扭转保留卵巢手术是否有助于在不增加术后并发症风险的情况下保留卵巢功能。方法:我们回顾性评估了2015年1月至2019年12月在延世大学医学院Severance医院手术诊断为附件扭转的71名女性(卵巢保存组,56名;卵巢切除术,15名)。将术前6个月测得的血清抗米勒激素(AMH)水平与术后6-24个月测到的水平进行比较。比较两组的手术结果和术后并发症。结果:卵巢切除术组和卵巢保存组术前和术后血清AMH水平的下降存在临界显著差异。两组在发热、感染或入院时间方面没有显著差异。卵巢保留组和卵巢切除术组中,分别有27.3%和33.3%的患者出现扭曲卵巢变色。有变色和无变色患者的血清AMH水平下降没有差异。结论:卵巢保留手术可能不会增加附件扭转患者的术后并发症,即使扭转的肿块被怀疑是坏死的。此外,如果保留了卵巢,卵巢储备可能不会受到扭转的影响。保守性卵巢手术可以安全地进行,以保留附件扭转和囊性肿块妇女的生殖潜力。
{"title":"Postoperative outcomes of ovarian preserving surgery in premenopausal women with adnexal torsion.","authors":"Euna Choi, Hye In Kim, Seok Kyo Seo, Si Hyun Cho, Young Sik Choi, Byung Seok Lee, Bo Hyon Yun","doi":"10.5468/ogs.23071","DOIUrl":"10.5468/ogs.23071","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to determine whether ovarian-preserving surgery for adnexal torsion helps preserve ovarian function without increasing the risk of postoperative complications.</p><p><strong>Methods: </strong>We retrospectively evaluated 71 women who were surgically diagnosed with adnexal torsion between January 2015 and December 2019 at Severance Hospital, Yonsei University College of Medicine (ovarian preservation group, 56; oophorectomy, 15). Serum anti-Müllerian hormone (AMH) levels measured within 6 months before surgery were compared to levels measured 6-24 months after surgery. Surgical findings and postoperative complications were compared between the groups.</p><p><strong>Results: </strong>There was a borderline significant difference in the decrease in serum AMH levels between the oophorectomy group and ovarian preservation group before and after surgery. There were no significant differences between the groups in terms of fever, infection, or duration of admission. Discoloration of the twisted ovary was found in 27.3% and 33.3% of the patients in the ovarian preservation and oophorectomy groups, respectively. There was no difference in the decrease in serum AMH levels between patients with and those without discoloration.</p><p><strong>Conclusion: </strong>Ovarian-preserving surgery may not increase postoperative complications in patients with adnexal torsion, even if a twisted mass is suspected to be necrotic. Moreover, the ovarian reserve may not be affected by torsion if the ovary is preserved. Conservative ovarian surgery can be safely performed to preserve the reproductive potential of women with adnexal torsion and cystic masses.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"562-571"},"PeriodicalIF":1.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of robotic sacrocolpopexy. 机器人骶骶固定术的结果。
IF 1.9 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2023-11-01 Epub Date: 2023-07-18 DOI: 10.5468/ogs.23073
Sumin Oh, Jung-Ho Shin

This review aimed to summarize the complications and surgical outcomes of robot-assisted sacrocolpopexy. Nineteen original articles on 1,440 robotic sacrocolpopexies were reviewed, and three systematic reviews and meta-analyses were summarized in terms of intraoperative, perioperative, postoperative, and/or surgical outcomes. Robotic sacrocolpopexy has demonstrated low overall complication rates and favorable surgical outcomes. Nevertheless, long-term follow-up outcomes regarding objective and/or subjective prolapse recurrence, reoperation rates, and mesh-related complications remain unclear. Further research is required to demonstrate whether the robotic approach for sacrocolpopexy is feasible or can become the modality of choice in the future when performing sacrocolpopexy.

本文综述了机器人辅助骶髋固定术的并发症和手术结果。我们回顾了19篇关于1440例机器人骶髋固定术的原创文章,并从术中、围术期、术后和/或手术结果方面总结了3篇系统综述和荟萃分析。机器人骶髋固定术显示出较低的总体并发症发生率和良好的手术效果。然而,关于客观和/或主观脱垂复发、再手术率和网状物相关并发症的长期随访结果仍不清楚。需要进一步的研究来证明机器人方法是否可行,或者是否可以成为未来进行骶髋固定术时的选择方式。
{"title":"Outcomes of robotic sacrocolpopexy.","authors":"Sumin Oh, Jung-Ho Shin","doi":"10.5468/ogs.23073","DOIUrl":"10.5468/ogs.23073","url":null,"abstract":"<p><p>This review aimed to summarize the complications and surgical outcomes of robot-assisted sacrocolpopexy. Nineteen original articles on 1,440 robotic sacrocolpopexies were reviewed, and three systematic reviews and meta-analyses were summarized in terms of intraoperative, perioperative, postoperative, and/or surgical outcomes. Robotic sacrocolpopexy has demonstrated low overall complication rates and favorable surgical outcomes. Nevertheless, long-term follow-up outcomes regarding objective and/or subjective prolapse recurrence, reoperation rates, and mesh-related complications remain unclear. Further research is required to demonstrate whether the robotic approach for sacrocolpopexy is feasible or can become the modality of choice in the future when performing sacrocolpopexy.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":"509-517"},"PeriodicalIF":1.9,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9824708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Obstetrics and Gynecology Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1